Equillium, Inc. (EQ) Key Metrics

NASDAQ: EQValuation, returns, debt and efficiency ratios over 9 years.

EQ valuation today

Trailing 12 months · as of October 17, 2026
Market cap
$75.5M
Enterprise value
$54.4M
P/E (TTM)
—
Forward P/E
1.5
PEG ratio
—
Price / sales
20.2
10-yr median 0.7
Price / book
2.2
10-yr median 1.4
EV / EBITDA
0.1
Dividend yield
—
Beta
1.92

EQ key metrics, 2017–2025

Fiscal year ended December 31, 2025 · U.S. dollars

EQ valuation Price multiples at each fiscal year-end price.

Price / book+258.8%
5.0
2025 · hover or tap a bar for each year
2019: 1.42020: 1.6 (+11.1%)2021: 1.6 (+4.7%)2022: 1.1 (−31.5%)2023: 1.1 (−0.6%)2024: 1.4 (+24.8%)2025: 5.0 (+258.8%)
20172025
Free cash flow yield+56.2 pts
−16.0%
2025 · hover or tap a bar for each year
2019: −39.2%2020: −22.8% (+16.4 pts)2021: −29.6% (−6.8 pts)2022: −25.2% (+4.4 pts)2023: −87.0% (−61.8 pts)2024: −72.2% (+14.7 pts)2025: −16.0% (+56.2 pts)
20172025

EQ valuation history

Fiscal year-endToday9-year median

EQ returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

EQ debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

EQ cash returned to shareholders

DividendsBuybacksFree cash flow

EQ price vs earnings per share

Share price at year-endEPS (right axis)

EQ key metrics

2017–2025
Equillium, Inc. key metrics by fiscal year
202520242023202220212020201920182017
Valuation
Market capitalization$142.4M$26.5M$25.1M$35.8M$108.6M$108.9M$58.7M——
Enterprise value$112.9M$4.3M−$14.9M−$25.1M$38.4M$36.7M$15.3M——
Price / sales—0.60.72.3—————
Price / book5.01.41.11.11.61.61.4——
EV / sales868.10.1-0.4-1.6—————
Earnings yield−15.7%−30.5%−53.1%−174.6%−35.9%−27.3%−43.5%——
Free cash flow yield−16.0%−72.2%−87.0%−25.2%−29.6%−22.8%−39.2%——
Dividend yield——36.4%———16.8%——
Shareholder yield (dividends + buybacks)—0.0%37.4%0.0%0.0%0.0%17.1%——
Share price at fiscal year-end$1.55$0.75$0.72$1.06$3.77$5.35$3.38$8.16—
Per share
Revenue per share$0.00$1.16$1.04$0.47$0.00$0.00$0.00—$0.00
Earnings per share−$0.24−$0.23−$0.38−$1.85−$1.35−$1.46−$1.47—−$0.14
Operating cash flow per share−$0.25−$0.54−$0.63−$0.26−$1.11−$1.21−$1.32—−$0.04
Free cash flow per share−$0.25−$0.54−$0.63−$0.27−$1.12−$1.22−$1.32—−$0.04
Cash per share$0.33$0.64$1.18$2.11$2.80$4.04$3.06—$0.43
Book value per share$0.31$0.54$0.65$0.95$2.31$3.43$2.41—−$0.13
Tangible book value per share$0.31$0.54$0.65$0.95$2.31$3.43$2.41—−$0.13
Dividends per share——$0.26———$0.57——
Capex per share$0.00$0.00$0.00$0.01$0.00$0.01$0.00—$0.00
Debt per share$0.01$0.01$0.02$0.30$0.37$0.49$0.56—$0.97
Shares outstanding91.9M35.4M34.7M33.7M28.8M20.4M17.4M—16.7M
Change in shares outstanding+159.9%+1.8%+3.0%+17.1%+41.5%+17.1%———
Returns & profitability
Return on equity (ROE)−94.0%−38.8%−48.9%−126.8%−57.2%−53.3%−47.9%−42.3%—
Return on invested capital (ROIC)————————−20.0%
Return on assets (ROA)−77.9%−21.2%−20.7%−76.2%−45.6%−42.2%−41.7%−35.7%−31.6%
Return on tangible assets−70.2%−31.5%−26.4%−79.6%−45.6%−34.8%−46.1%−19.7%−31.6%
Free cash flow margin—−46.5%−60.5%−57.2%—————
Financial health
Total debt$719,000$384,000$824,000$10.2M$10.6M$9.9M$9.7M$200,000$16.1M
Cash & short-term investments$30.3M$22.6M$40.9M$71.0M$80.7M$82.2M$53.1M$65.9M$7.1M
Net debt−$29.6M−$22.2M−$40.0M−$60.8M−$70.2M−$72.2M−$43.5M−$65.7M$9.0M
Debt / equity0.030.020.040.320.160.140.230.00—
Debt / assets0.020.010.020.130.120.120.170.002.25
Current ratio10.323.931.792.409.4011.7914.3033.1212.57
Quick ratio10.323.931.792.409.4011.7914.3033.1212.57
Interest coverage——-29.6-59.0-35.2-26.9-95.8-3.4-4.5
Working capital$27.3M$18.6M$21.8M$44.7M$74.8M$78.2M$51.7M$65.1M$6.6M
Invested capital−$961,000−$3.1M−$17.5M−$28.9M−$3.7M−$2.4M−$1.6M−$778,000$6.8M
Tangible asset value$28.6M$19.1M$22.6M$31.9M$66.5M$69.9M$41.8M$64.9M−$2.3M
Net current asset value$27.0M$18.4M$21.4M$30.3M$64.9M$69.9M$41.8M$64.9M−$2.3M
Graham net-net per share$0.29$0.48$0.51$0.82$2.15$3.27$2.27—−$0.14
Capital allocation
Dividends paid——$9.1M———$9.9M——
Share buybacks (net)—$0$260,000$0$0$0$156,000$0$0
Capex / revenue36.9%0.2%0.1%1.8%—————
Capex / depreciation0.410.620.402.360.794.493.225.7118.02
Stock-based compensation / revenue1,786.2%9.1%11.1%30.7%—————
R&D / revenue9,879.2%91.1%102.6%238.3%—————
SG&A / revenue8,300.8%29.0%37.9%109.4%—————
Efficiency
Days sales outstanding1,757.633.052.647.6—————
Days payables outstanding5,397.99,835.012,578.08,045.510,116.118,813.723,740.940,757.2729,225.1
Cash conversion cycle (days)-3,640.3-9,802.0-12,525.4-7,997.8—————
Receivables turnover0.2111.066.947.66—————
Payables turnover0.070.040.030.050.040.020.020.010.00
Asset turnover0.001.080.560.190.000.000.000.000.00
Average receivables$626,000$3.7M$5.2M$2.1M$0————
Average payables$1.7M$3.7M$4.3M$2.6M$2.0M$2.3M$1.5M$681,370$243,741
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.1%0.0%0.0%

Computed from EQ's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

EQ valuation and financial ratios

Equillium earned a return on equity of −94.0% in fiscal 2025. It ended the year with $0.7 million of debt and $30.3 million in cash and short-term investments, a net cash position of $29.6 million. The share count rose 450.3% from 16.7M to 91.9M over 8 years.

See the EQ income statement, the EQ chart for price history, or the EQ stock overview for the latest quote and news.

EQ key metrics FAQ

What is Equillium's return on equity?

Equillium's return on equity (ROE) was −94.0% in fiscal 2025: net income of -$22.4 million on average shareholders' equity of $23.8 million.

How much debt does Equillium have?

Equillium had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.

What is Equillium's free cash flow yield?

Equillium generated -$22.8 million of free cash flow in fiscal 2025, a free cash flow yield of −16.0% on its market value at year-end ($142.4 million).

What is Equillium's current ratio?

Equillium's current ratio was 10.32 at the end of fiscal 2025: current assets were 10.32 times current liabilities.

Biotechnology key metrics